Trial Profile
A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2011
Price :
$35
*
At a glance
- Drugs Nanatinostat/valganciclovir combination therapy (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 25 Nov 2011 Actual patients number (40) added as reported by ClinicalTrials.gov.
- 25 Nov 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 25 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.